Patients with unrecognized or prodromal Parkinson's disease (PPD) experience problems with mobility, muscle weakness, and struggle with other aspects of daily functioning up to 3 years before ...
Absence of photophobia at 2 hours postdose occurred in 19.5 and 12.5% of ubrogepant- and placebo-treated events, respectively. HealthDay News — Ubrogepant during the prodromal phase of migraine may ...
As research continues to advance, the ability to detect and intervene in neurodegenerative disease at its earliest stages ...
Please provide your email address to receive an email when new articles are posted on . Increased consumption of unprocessed foods boosted odds of nonmotor prodromal Parkinson’s symptoms. Greater odds ...
Mild cognitive impairment has been proposed as a marker for the prodromal phase of Parkinson disease (PD), but little is known about its presentation in community-dwelling older adults. A recent study ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Individuals with prodromal or unrecognized Parkinson’s ...
Several known risk factors and prodromal features were associated with Parkinson disease, including traumatic brain injury and alcohol misuse, along with other comorbidities such as skin and ...
The clinical utility of the calcitonin gene–related peptide (CGRP) receptor antagonist ubrogepant may extend beyond the treatment of acute migraine to alleviating common prodromal symptoms of migraine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results